標(biāo)題: Titlebook: Botulinum Toxin Treatment of Pain Disorders; Bahman Jabbari Book 20151st edition Springer Science+Business Media New York 2015 Analgesic.B [打印本頁(yè)] 作者: Precise 時(shí)間: 2025-3-21 18:53
書目名稱Botulinum Toxin Treatment of Pain Disorders影響因子(影響力)
書目名稱Botulinum Toxin Treatment of Pain Disorders影響因子(影響力)學(xué)科排名
書目名稱Botulinum Toxin Treatment of Pain Disorders網(wǎng)絡(luò)公開度
書目名稱Botulinum Toxin Treatment of Pain Disorders網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Botulinum Toxin Treatment of Pain Disorders被引頻次
書目名稱Botulinum Toxin Treatment of Pain Disorders被引頻次學(xué)科排名
書目名稱Botulinum Toxin Treatment of Pain Disorders年度引用
書目名稱Botulinum Toxin Treatment of Pain Disorders年度引用學(xué)科排名
書目名稱Botulinum Toxin Treatment of Pain Disorders讀者反饋
書目名稱Botulinum Toxin Treatment of Pain Disorders讀者反饋學(xué)科排名
作者: 多嘴 時(shí)間: 2025-3-21 23:54
https://doi.org/10.1007/978-3-540-33640-2Investigations using botulinum neurotoxins (BoNTs) in management of tension-type headache have also provided negative results, but the results are confounded by selection of low-dose, suboptimal technique and selection of rigid primary outcome criteria. No blinded studies with BoNTs are available fo作者: bile648 時(shí)間: 2025-3-22 01:44
Long-Term Preservation of Digital Documentslevel C) in chronic low back pain. Future studies should focus on etiologically distinct subgroups of patients with chronic LBP and take advantage of using the dose and techniques that have already shown promising results.作者: 尖牙 時(shí)間: 2025-3-22 04:53 作者: keloid 時(shí)間: 2025-3-22 09:15 作者: 世俗 時(shí)間: 2025-3-22 14:53 作者: 繞著哥哥問 時(shí)間: 2025-3-22 18:25
Uwe M. Borghoff,Peter R?dig,Jan Scheffczykuture studies..Currently, a significant level of efficacy for local use of botulinum toxins can be ascribed only for trigeminal neuralgia (one class I study, level B, probably effective). In temporomandibular pain, data generated from retrospective studies and observation of experienced clinicians s作者: SYN 時(shí)間: 2025-3-22 22:09 作者: Hemiplegia 時(shí)間: 2025-3-23 02:38
Migration: Current Research and Developmentrefractory pain after total knee arthroplasty and local painful arthritis and anterior knee pain related to vastus lateralis imbalance (each with one class II study). While these positive data are encouraging, better designed, high-quality, and controlled studies (class I and II) are needed for opti作者: 攀登 時(shí)間: 2025-3-23 08:00 作者: Cytology 時(shí)間: 2025-3-23 11:47
Botulinum Neurotoxins and Chronic Low Back Pain,level C) in chronic low back pain. Future studies should focus on etiologically distinct subgroups of patients with chronic LBP and take advantage of using the dose and techniques that have already shown promising results.作者: 我們的面粉 時(shí)間: 2025-3-23 16:51
Botulinum Toxin Treatment of Plantar Fasciitis (Plantar Fasciopathy),tulinum toxin A is a relatively novel treatment for PF. The results of two double-blind, placebo-controlled studies have supported its efficacy (level B). A comparator-blinded study has shown that BoNT-A is more effective than betamethasone in relieving pain and improving function at 6 months. Furth作者: FEAS 時(shí)間: 2025-3-23 18:38
Botulinum Toxin Treatment of Myofascial Pain Syndrome and Fibromyalgia,ns controversial, there is hope that future studies taking advantage of our current knowledge derived from positive studies can provide further support for the role of BoNT in management of myofascial pain syndrome..Fibromyalgia is a systemic disease characterized by diffuse muscle pain, fatigue, he作者: Critical 時(shí)間: 2025-3-24 02:08 作者: Solace 時(shí)間: 2025-3-24 02:32 作者: nerve-sparing 時(shí)間: 2025-3-24 10:34
Botulinum Neurotoxins for Relief of Pain Associated with Spasticity,olled studies. One study demonstrated efficacy for onaA using a validated pain scale (level B, probably effective) and another for aboA using a scale of 0–5 for assessment of pain. In cerebral palsy (CP), one blinded study reported significant relief of spasticity-related pain after administration o作者: GEON 時(shí)間: 2025-3-24 12:25
Botulinum Toxins for Treatment of Pain in Orthopedic Disorders,refractory pain after total knee arthroplasty and local painful arthritis and anterior knee pain related to vastus lateralis imbalance (each with one class II study). While these positive data are encouraging, better designed, high-quality, and controlled studies (class I and II) are needed for opti作者: crescendo 時(shí)間: 2025-3-24 17:54 作者: LINES 時(shí)間: 2025-3-24 22:32
Molecular Structure, Mode of Action, and Immunology of Botulinum Neurotoxins,tions (sialorrhea and hyperhidrosis), spasticity, and chronic migraine. Further indications in other pain disorders are being actively explored based on animal studies and laboratory data indicating an analgesic effect for BoNTs through diverse mechanisms..This chapter provides an overview of the mo作者: 胰臟 時(shí)間: 2025-3-25 01:56
Analgesic Effects of Botulinum Neurotoxins: Data from Animal Studies,of the pathophysiology of pain. Data generated from animal models indicate that botulinum toxins can modify and subdue a variety of mechanisms that generate or maintain pain..The first part of this chapter provides a brief overview of the pathophysiology of pain in light of some of the new developme作者: 壯麗的去 時(shí)間: 2025-3-25 05:56
Neuropathic Pain (NP), conventional treatment of common categories of neuropathic pain and reviews the literature on botulinum neurotoxin (BoNT) efficacy in neuropathic pain. The level of efficacy for BoNT treatment in each category is defined according to the published guidelines of the American Academy of Neurology. Th作者: 準(zhǔn)則 時(shí)間: 2025-3-25 08:30
Migraine and Other Primary Headaches,pe headaches are common and, in chronic form, are major causes of disability. Prospective double-blind and placebo-controlled studies have confirmed the efficacy of onabotulinumtoxinA (onaA) in chronic migraine (class A evidence). Follow-up of patients in PREEMPT studies with five cycles of onaA inj作者: ARC 時(shí)間: 2025-3-25 12:22 作者: ANT 時(shí)間: 2025-3-25 19:40 作者: eustachian-tube 時(shí)間: 2025-3-25 23:28
Botulinum Toxin Treatment of Piriformis Syndrome,rby sciatic nerve (or one of its major divisions) by a tense and overactive piriformis muscle. Current treatments consist of stretching exercises, oral medications, and anesthetic or steroid injections; these approaches are only partially effective. Two double-blind, placebo-controlled studies have 作者: carotenoids 時(shí)間: 2025-3-26 01:43
Botulinum Toxin Treatment of Myofascial Pain Syndrome and Fibromyalgia,nt of myofascial pain syndrome is partially successful with conventional analgesics, but a large number of patients remain unsatisfied..Botulinum neurotoxins (BoNTs) can relieve myofascial pain by blocking the release of acetylcholine and pain mediators (substance P, glutamate, calcitonin gene-relat作者: 不感興趣 時(shí)間: 2025-3-26 05:09 作者: monopoly 時(shí)間: 2025-3-26 08:46 作者: 可憎 時(shí)間: 2025-3-26 15:40
Botulinum Neurotoxins for Relief of Pain Associated with Spasticity,atment, although effective, is confounded by undesirable side effects and short duration of response. Botulinum neurotoxins (BoNTs) have been approved by FDA for treatment of spasticity. The role of BoNT therapy in spasticity-related pain is less established. In this chapter, the literature from dou作者: defeatist 時(shí)間: 2025-3-26 18:22
Treatment of Dystonic Pain with Botulinum Neurotoxins,onias, namely, cervical dystonia, focal dystonia associated with neurodegenerative disorders, and post-traumatic dystonia. The literature on the efficacy of botulinum toxins for these three forms of dystonic pain is reviewed. Fourteen blinded and placebo-controlled clinical trials assessed pain at b作者: THROB 時(shí)間: 2025-3-26 22:33
Botulinum Toxin Therapy for Prevention of Postsurgical Pain,pain results in application of polypharmacy and may lead to lengthy hospitalization..This chapter reviews the data in intraoperative, intramuscular, or intra-sphincteric use of botulinum neurotoxins (BoNTs) for relief of postsurgical pain. As examples, five areas of postsurgical pain are chosen in w作者: Thyroiditis 時(shí)間: 2025-3-27 04:07
Botulinum Toxins for Treatment of Pain in Orthopedic Disorders,ging interest in exploring the potential role for BoNTs in relieving orthopedic pain..In this chapter, the data on BoNT therapy in four orthopedic disorders for which placebo-controlled studies are available are presented. These disorders consist of chronic lateral epicondylitis, painful local arthr作者: 擔(dān)心 時(shí)間: 2025-3-27 07:26 作者: AGONY 時(shí)間: 2025-3-27 12:37
Botulinum Neurotoxin Treatment of Unusual and Rare Painful Disorders,g the release of pain mediators such as calcitonin gene-related peptide (CGRP), glutamate, substance P (SP), and others (detailed in Chap. 2). In addition to the common pain disorders discussed in the preceding chapters, data is now available on the possible efficacy of BoNTs in alleviating pain in 作者: Enthralling 時(shí)間: 2025-3-27 15:59 作者: Hearten 時(shí)間: 2025-3-27 21:50 作者: Infraction 時(shí)間: 2025-3-27 23:58 作者: 飛鏢 時(shí)間: 2025-3-28 04:42 作者: 法律 時(shí)間: 2025-3-28 09:12
Molecular Structure, Mode of Action, and Immunology of Botulinum Neurotoxins,on animal studies and laboratory data indicating an analgesic effect for BoNTs through diverse mechanisms..This chapter provides an overview of the molecular structure, pharmacological characteristics, mode of action, immunology, and side effects of botulinum neurotoxins.作者: Harness 時(shí)間: 2025-3-28 13:08
Analgesic Effects of Botulinum Neurotoxins: Data from Animal Studies,nts. The second part provides a focused review of the literature on how botulinum neurotoxins improve and modify animals’ response to pain as well as the therapeutic influence of these toxins on pain receptors, channels, and mediators.作者: 熱心助人 時(shí)間: 2025-3-28 16:23 作者: CREST 時(shí)間: 2025-3-28 20:02 作者: keloid 時(shí)間: 2025-3-29 02:44
Aging Effects in Sequential Elementsrmia—are discussed. The limited data from the literature about the use of BoNT in these conditions is presented. Case reports and video clips are included from the author’s experience to illustrate the clinical features and the technique of BoNT injection employed to relieve pain.作者: CANE 時(shí)間: 2025-3-29 04:55 作者: 墊子 時(shí)間: 2025-3-29 07:51
Botulinum Neurotoxin Treatment of Unusual and Rare Painful Disorders,rmia—are discussed. The limited data from the literature about the use of BoNT in these conditions is presented. Case reports and video clips are included from the author’s experience to illustrate the clinical features and the technique of BoNT injection employed to relieve pain.作者: 聯(lián)想 時(shí)間: 2025-3-29 13:33
Migration: Current Research and Developmentnal pain syndrome, and chemotherapy-induced allodynia. Controlled studies are necessary to assess the efficacy of BoNTs in these conditions. Much remains to be learned about the most effective dosage and technique of injection, optimum dilutions, and differences among BoNTs in the treatment of neuropathic pain.作者: 征服 時(shí)間: 2025-3-29 17:02
Long-Term Preservation of Digital Documents or B) improve pain of Parkinson-related dystonias (toe flexion and foot inversion) as well as painful post-traumatic dystonias. Blinded studies for these indications are not available. Case reports and short videotape clips from author’s experience are provided to demonstrate patients’ histories and the technique of BoNT administration.作者: 最初 時(shí)間: 2025-3-29 22:39
Long-Term Preservation of Digital Documentscy of botulinum neurotoxins (mainly onabotulinumtoxinA) for prevention of postsurgical pain but also suggest that treatment with BoNTs in these syndromes may have predictive value regarding the efficacy of certain surgical procedures which are currently employed to relieve such pains.作者: 牢騷 時(shí)間: 2025-3-30 01:28
Neuropathic Pain (NP),nal pain syndrome, and chemotherapy-induced allodynia. Controlled studies are necessary to assess the efficacy of BoNTs in these conditions. Much remains to be learned about the most effective dosage and technique of injection, optimum dilutions, and differences among BoNTs in the treatment of neuropathic pain.作者: 套索 時(shí)間: 2025-3-30 06:13 作者: 金哥占卜者 時(shí)間: 2025-3-30 08:44 作者: EXALT 時(shí)間: 2025-3-30 13:56
https://doi.org/10.1007/978-3-540-33640-2nts. The second part provides a focused review of the literature on how botulinum neurotoxins improve and modify animals’ response to pain as well as the therapeutic influence of these toxins on pain receptors, channels, and mediators.作者: 致詞 時(shí)間: 2025-3-30 18:50
Long-Term Preservation of Digital DocumentsFurthermore, single-case observations with onabotulinumtoxinA have shown that local intramuscular injection of this toxin can alleviate chronic and disabling local pain in advanced cancer and improve the quality of the end of life state among patients with terminal cancer.作者: Axillary 時(shí)間: 2025-3-30 23:32 作者: notice 時(shí)間: 2025-3-31 02:45 作者: 小卷發(fā) 時(shí)間: 2025-3-31 05:29
Bahman JabbariEvidenced based comprehensive literature review of botulinum neurotoxin efficacy in each indication.A comprehensive account of botulinum neurotoxin treatment in pain indications in clinical medicine.F作者: bourgeois 時(shí)間: 2025-3-31 10:05
http://image.papertrans.cn/b/image/189965.jpg作者: palliative-care 時(shí)間: 2025-3-31 16:28
Future Prospects of Pain Treatment with Botulinum Neurotoxins,ry neurons can offer a more effective means of pain control. The preliminary data from cell culture and animal experiments suggest a significant potential for these toxins/toxin chimeras and toxin/antibody compounds in relieving human pain.作者: landfill 時(shí)間: 2025-3-31 21:10 作者: CREEK 時(shí)間: 2025-3-31 22:25
https://doi.org/10.1007/978-3-540-33640-2of the pathophysiology of pain. Data generated from animal models indicate that botulinum toxins can modify and subdue a variety of mechanisms that generate or maintain pain..The first part of this chapter provides a brief overview of the pathophysiology of pain in light of some of the new developme作者: 輕推 時(shí)間: 2025-4-1 02:20
Migration: Current Research and Development conventional treatment of common categories of neuropathic pain and reviews the literature on botulinum neurotoxin (BoNT) efficacy in neuropathic pain. The level of efficacy for BoNT treatment in each category is defined according to the published guidelines of the American Academy of Neurology. Th
